Patents Examined by Richard A. Schwartz
  • Patent number: 5316910
    Abstract: The present invention relates to nucleoprotein (NP) genes of the influenza A and B viruses which were constructed from virion RNA and subsequently expressed in Spodoptera frugiperda (S19) cells using the baculovirus vector, Autographa californica nuclear polyhedrosis virus (AcNPV). Western blot analysis of lysates prepared from S19 cells infected with the recombinant viruses confirmed that the baculovirus-expressed NP antigens were reactive with monoclonal antibodies specific for either type A or B NP and with anti-NP antibodies in human serum samples. Electrophoretic analysis indicated that the expressed influenza NP antigens comigrated with NP purified from influenza A or B virions and that the recombinant NP antigens represented greater than 10% of total protein in infected cells. Dilutions of clarified S19 cell lysates were used as antigens in a standard enzyme immunoassay format to detect serum antibody specific for influenza A or B viruses.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: May 31, 1994
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Paul A. Rota, Renee A. Black
  • Patent number: 5316946
    Abstract: A small, novel transposon useful for mutagenesis and sequencing DNAs cloned in phage .lambda. is disclosed which comprises a transposon having at each terminus a segment of 19 nucleotides selected from the group consisting of the O-end and I-end sequences of Tn5, at least one restriction enzyme site positioned less that 20 nucleotides distant from each said terminal segment, and a supF amber-suppressor tRNA gene insert.
    Type: Grant
    Filed: January 22, 1990
    Date of Patent: May 31, 1994
    Assignee: Washington University
    Inventors: Suhas H. Phadnis, Henry V. Huang, Doulgas E. Berg
  • Patent number: 5314818
    Abstract: Disclosed are novel variants of tissue plasminogen activator (t-PA) that have surprising biological/pharmacokinetic properties compared with native t-PA. For example, certain of the variants hereof demonstrate increased half-life profiles, and show good fibrin binding activity even though fibrin binding regions of the molecule are deleted. All associated means and methods for preparing such variants recombinantly and for using such variants are also disclosed.
    Type: Grant
    Filed: February 19, 1992
    Date of Patent: May 24, 1994
    Assignee: Genentech, Inc.
    Inventors: Stephen P. Anderson, Deborah L. Higgins, Adair J. Hotchkiss, Cara B. Marks
  • Patent number: 5312909
    Abstract: A transformed yeast is disclosed, comprising at least one gene encoding neutral trehalase or trehalose-6-phosphate synthase which gene has been modified such that it differs from a corresponding wild-type gene encoding neutral trehalase or trehalose-6-phosphate synthase, the yeast having as a result a different trehalose content from the untransformed parent yeast. The sugar resistance and drying resistance of the yeast compared to those of the untransformed strain are thereby improved.
    Type: Grant
    Filed: March 22, 1991
    Date of Patent: May 17, 1994
    Assignee: Gist Brocades, N.V.
    Inventors: Marianne Driessen, Klaas A. Osinga, Margareta A. Herweijer
  • Patent number: 5310678
    Abstract: Recombinant DNA encoding a polypeptide precursor of the HN or F glycoprotein of Newcastle Disease Virus has been prepared and sequenced.
    Type: Grant
    Filed: November 17, 1989
    Date of Patent: May 10, 1994
    Assignee: National Research Development Corporation
    Inventors: Richard W. Bingham, Philip Chambers, Peter T. Emmerson, Neil S. Millar
  • Patent number: 5310677
    Abstract: A method of increasing xanthan gum production, comprising culturing a Xanthomonas campestris strain having a xanthan-increasing modification in a culture medium, wherein the modification is selected from the group consisting of (1) a mutation causing rifampicin-resistance; (2) a mutation causing bacitracin-resistance; or (3) exogenous genetic information controlling the synthesis of xanthan; and separating xanthan from the culture medium, is provided along with specific DNA sequences and Xanthomonas campestris strains showing increased xanthan gum production.
    Type: Grant
    Filed: November 5, 1992
    Date of Patent: May 10, 1994
    Assignees: Shin-Etsu Chemical Co., Ltd., Shin-Etsu Bio, Inc.
    Inventors: Thomas J. Pollock, Linda Thorne
  • Patent number: 5310671
    Abstract: The invention relates to DNA from fowlpox virus (FPV) providing a non-essential region for the insertion of foreign genes thereinto and thence the construction of a vector for homologous recombination with a wild type FPV, whereby the resulting recombinant FPV can be used for vaccination of animals, especially chickens. In this invention, the non-essential region consists substantially of a length of DNA from the long unique sequence of the terminal inverted repeat (TIR) of FPV or from the region at FPV which corresponds approximately to the HindIII D fragment genes D8 and D9 in vaccinia virus.
    Type: Grant
    Filed: November 28, 1990
    Date of Patent: May 10, 1994
    Assignee: British Technology Group Limited
    Inventors: Matthew M. Binns, Michael E. G. Boursnell, Joan I. A. Campbell, Fiona M. Tomley
  • Patent number: 5310661
    Abstract: DNA encoding the prepro inhibin .alpha. and .beta. chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibin .alpha. or .beta. chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.
    Type: Grant
    Filed: October 8, 1992
    Date of Patent: May 10, 1994
    Assignee: Genentech, Inc.
    Inventors: Anthony J. Mason, Peter H. Seeburg
  • Patent number: 5310894
    Abstract: Methods for solid-state synthesis of polymers, especially polypeptides and polynucleotides, are provided. In accordance with a preferred embodiment, selectively activatable and reactive bonding moieties are covalently bonded to solid supports for polynucleotide and polypeptide syntheses. Products of failed reactions and some side products are caused to react with the selectively activatable and reactive bonding moiety to cause divalent bonding of unwanted products to the solid support. Upon cleavage of the initial situs of covalent bonding to the solid support, desired products are free to be collected while unwanted products remain covalently bonded to the support. Ease of purification of such polymers is a principal object of the present invention. The methods of the invention are amenable to automation and digital control and novel solid supports, activatable, reactive bonding moieties and other compositions are presented.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: May 10, 1994
    Assignee: Thomas Jefferson University
    Inventor: Allen R. Zeiger
  • Patent number: 5310668
    Abstract: A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Elliott Kieff, Edward M. Scolnick, Robert S. Lowe
  • Patent number: 5310654
    Abstract: Novel methods and microorganisms are provided, where novel genetic mammalian cell invasive capability is imparted to a microorganism by the introduction of an exogenous inv or ail gene. The resulting organisms are then capable of binding to mammalian cells and are transferred to the cytoplasm. Other novel genetic capabilities may be imparted to the unicellular microorganism, which may serve as a vaccine for one or more pathogens or may introduce genetic capabilities or foreign molecules into a mammalian host cell. The sequences may be used for an in vitro screen for pathogenicity.
    Type: Grant
    Filed: April 19, 1989
    Date of Patent: May 10, 1994
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ralph R. Isberg, Virginia Miller, Stanley Falkow
  • Patent number: 5306635
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
    Type: Grant
    Filed: June 9, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Paul M. Keller, Mark W. Riemen, Ronald W. Ellis, Andrew J. Davison, Robert S. Lowe
  • Patent number: 5304471
    Abstract: A process of producing a foreign protein is provided which comprises transforming E. coli with a plasmid carrying a fused DNA having a DNA fragment encoding a foreign protein located downstream of a transcription initiation signal and translation initiation signal both derived from an appropriate T4 phage gene, infecting the transformant with a T4 phase denB and/or alc mutant at a low multiplicity of infection, and then culturing the infected transformant. The desired foreign protein can be produced in an extremely high yield, as compared to the prior art technique.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: April 19, 1994
    Assignee: Yamasa Shoyu Kabushiki Kaisha
    Inventors: Toshitada Noguchi, Hideo Takahashi
  • Patent number: 5304482
    Abstract: The present invention relates to serine protease mutants of the chymotrypsin superfamily that are resistant to inhibition by their cognate inhibitors, and genes that encode the same. The present invention also relates to serine protease inhibitor mutants that inhibit the serine protease mutants of the present invention, and genes that encode the same. The serine protease mutants and serine protease inhibitor mutants are useful as, e.g., pharmacological agents.
    Type: Grant
    Filed: September 28, 1990
    Date of Patent: April 19, 1994
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Joseph F. Sambrook, Edwin L. Madison, Elizabeth J. Goldsmith, Maryjane H. Gething
  • Patent number: 5304640
    Abstract: The invention relates to glycoprotein ligands of selectins. The invention further relates to methods and means for preparing and to nucleic acids encoding these ligands. The invention further concerns a method of treating a symptom or condition associated with excessive binding of circulating leukocytes to endothelial cells by administering to a patient in need of such treatment a glycoprotein ligand of a selectin.
    Type: Grant
    Filed: February 13, 1992
    Date of Patent: April 19, 1994
    Assignees: Genentech, Inc., Regents of the University of California
    Inventors: Laurence A. Lasky, Yasuyuki Imai, Steven D. Rosen, Mark S. Singer
  • Patent number: 5302529
    Abstract: Genomic and cDNA sequences coding for a protein having substantially the same biological activity as human protein C are disclosed. Recombinant plasmids and bacteriophage transfer vectors incorporating these sequences are also disclosed.
    Type: Grant
    Filed: April 23, 1990
    Date of Patent: April 12, 1994
    Assignee: The Board of Regents of the University of Washington
    Inventors: Donald C. Foster, Earl W. Davie
  • Patent number: 5302527
    Abstract: The invention relates to use of the nitrate reductase gene as a selection marker in transformations of the antibiotic-producing species Penicillium chrysogenum and Acremonium chrysogenum. In particular it relates to a process for obtaining cells of Penicillium chrysogenum or Acremonium chrysogenum capable of expressing nitrate reductase from cells of the same species which are initially deficient in expression of the nitrate reductase gene (niaD-cells), which comprises introducing into said niaD-cells vector DNA including a marker gene coding for nitrate reductase operatively linked to a control sequence for expression of said gene within the selected host cells, followed by selection of cells thus transformed by their ability to grow on a suitable medium containing nitrate as the only source of nitrogen and to vector DNA for use in such a process.
    Type: Grant
    Filed: November 9, 1990
    Date of Patent: April 12, 1994
    Assignee: Glaxo Group Limited
    Inventors: John A. Birkett, James R. Kinghorn
  • Patent number: 5302698
    Abstract: This invention relates to a DNA coding for a protein that specifically binds to the enhancer of the .alpha.-fetoprotein gene and that promotes transcription of that .alpha.-fetoprotein gene. This DNA is useful, by applying recombinant DNA technology, for the construction of highly efficient gene expression system for the production of proteins having physiological activities in animal cells.
    Type: Grant
    Filed: February 17, 1993
    Date of Patent: April 12, 1994
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Tomonori Morinaga, Hisataka Yasuda, Kanji Higashio, Taiki Tamaoki
  • Patent number: 5300434
    Abstract: Methods of determining collagen degradation in vivo, by quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. Suitable methods include immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structure of specific peptides having cross-links and kits for quantitating these peptides in a body fluid are described.
    Type: Grant
    Filed: November 21, 1990
    Date of Patent: April 5, 1994
    Assignee: Washington Research Foundation
    Inventor: David R. Eyre
  • Patent number: 5300431
    Abstract: Positive selection cassettes are disclosed which contain a lethal gene, a promoter, a repressor sequence overlapping the promoter, and a cloning site between the promoter and the lethal gene. Insertion of a foreign nucleic acid sequence into the cloning site prevents expression of the lethal gene. Expression of the lethal gene under nonrepressed conditions kills a host organism containing a positive selection cassette which does not contain the foreign nucleic acid sequence.
    Type: Grant
    Filed: February 26, 1991
    Date of Patent: April 5, 1994
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: James C. Pierce, Nat L. Sternberg